Why Twist Bioscience Stock Is Back in Focus

Twist Bioscience (TWST) moved back onto investors' radar after raising revenue guidance for fiscal 2026 and the fourth quarter, along with new commentary on demand for its DNA synthesis platform and product portfolio.

The updated outlook was followed by a completed common stock offering, which added fresh capital but also expanded the share count. That combination of higher guidance and new equity makes timing and pricing key considerations for anyone tracking the stock.

The share price reaction has been sharp. Twist Bioscience has a 1 day share price return of 6.04%, a 7 day share price return of 26.35% and a 90 day share price return of 103.47%. The 1 year total shareholder return is 351.13%, suggesting momentum has been building as investors respond to higher revenue guidance, the recent equity raise and fresh commentary on demand for its DNA synthesis platform.

If Twist Bioscience's recent move has you looking across the sector, this is a good moment to scan other fast growing AI linked plays using the 68 profitable AI stocks that aren't just burning cash

Twist Bioscience now sits at the crossroads of stronger revenue guidance and a sharply higher share price. The business case looks clearer. The harder question is whether the current valuation already reflects it.

Most Popular Narrative: 25% Overvalued

The most followed narrative values Twist Bioscience at $92.50 per share, which sits below the recent $115.67 close and puts extra scrutiny on the current rally.

Diversification across multiple end markets and geographies, coupled with strong underlying industry trends like AI-driven drug discovery and global genomics market expansion, provides resilience against market cycles and supports steady, long-term revenue and profit growth.

Want to see what sits behind that confidence in Twist Bioscience? The core narrative leans heavily on brisk revenue expansion, margin lift and a rich future earnings multiple.

Result: Fair Value of $92.50 (OVERVALUED)

However, there is still meaningful risk for Twist Bioscience if heavy customer concentration in NGS and the ongoing net loss of $136.717 million begin to weigh more heavily on sentiment.

Another View on Twist Bioscience's Valuation

The narrative price target for Twist Bioscience points to shares trading around 25% above a $92.50 fair value. The SWS DCF model tells a very different story. It suggests fair value closer to $203.26 per share, which is above the current $115.67 price. Which signal do you trust more right now?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Twist Bioscience for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

This mix of optimism and caution around Twist Bioscience will not stay under the radar for long. Take time now to review the numbers, weigh the story and check the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Twist Bioscience?

If Twist Bioscience has sharpened your focus, do not stop here. Use the Simply Wall St screener to compare fresh opportunities before the next move passes you by.

• Target potential mispriced opportunities by scanning companies that score well on quality and valuation through the 51 high quality undervalued stocks.
• Prioritise resilience by searching for businesses that pair lower risk profiles with steady fundamentals using the 79 resilient stocks with low risk scores.
• Hunt for lesser known opportunities by checking the screener containing 19 high quality undiscovered gems that combine solid metrics with limited market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.